A rare case of flupirtine induced loss of speech.
Journal Title: Journal of Drug Discovery and Therapeutics - Year 2015, Vol 3, Issue 3
Abstract
Anarthria can be caused by CNS depressant drugs but flupirtine consumption leading to it, is not documented till date. Since it is a drug with unique properties and is being more commonly used by practitioners, caution needs to be taken in noting rare adverse effects. In this short communication, a case of flupirtine induced loss of speech is reported.
Authors and Affiliations
Niroop Revannasiddaiah| Assistant Professor, Department of Pharmacology, PES Institute of Medical Sciences and Research., Chandani Ashok Kumar| Assistant Professor, Department of Community Medicine, PES Institute of Medical Sciences and Research.
Keywords
Related Articles
- EP ID EP1702
- DOI -
- Views 472
- Downloads 27
IMPROVEMENT OF FAST DISINTEGRATING TABLETS USING RANITIDINE HCL
The present study was designed towards the design and development of fast disintegrating tablets by direct compression technology using Ranitidine HCl as a model drug. Fast disintegrating tablet of Ranitidine HCl was for...
LUBIPROSTONE: A NOVEL DRUG TO TREAT CONSTIPATION
Lubiprostone, a bicyclic fatty acid, is a novel drug of new class of agents called prostones. It is approved by US FDA for the treatment of chronic constipation and constipation associated irritable bowel syndrome (IBS-...
Gastrointestinal mucoadhesive drug delivery system: an overview
The current article has been focused on the mucoadhesive drug delivery system. Mucoadhesive drug delivery system shows promising future in enhancing the bioavailability and specific needs by utilizing the physiological c...
Formulation and evolution of matrix tablets- a review
Formulations that are able to control the release of drug have become an integral part of the pharmaceutical industry. Many of the pharmaceutical dosage form are formulated as sustained release dosage form to retard the...
FORMULATION, OPTIMIZATION AND EVALUATION OF FAST DISSOLVING ORAL FILM OF DOMPERIDONE
Fast dissolving dosage form (FDDF) is designed to allow administration of an oral solid dose form in the absence of water or fluid intake. Such formulation readily dissolve or disintegrate in the saliva generally within...